Last updated: February 4, 2026
Case Overview
Orexo AB filed suit against Actavis Elizabeth LLC on September 14, 2016, in the District of Delaware. The case centers on patent infringement allegations related to OXBRIDGE (buprenorphine/naloxone) products. Orexo owns U.S. Patent No. 8,603,514 (the '514 patent), which covers specific formulations of buprenorphine and naloxone. Orexo asserts that Actavis’s generic versions infringe this patent, aiming to block market entry under the Hatch-Waxman Act.
Patent Details
- Patent Number: 8,603,514
- Filing Date: September 14, 2011
- Issue Date: December 3, 2013
- Claim Scope: The patent claims specific formulations of buprenorphine/naloxone with a particular ratio and controlled-release properties.
Legal Claims
- Infringement of the '514 patent through manufacture, use, and sale of Actavis's generic buprenorphine/naloxone products.
- Seek for injunction to prevent FDA approval or sale of infringing generics.
- Monetary damages for willful infringement.
Procedural History
- Initial Complaint: Filed September 2016.
- Preliminary Injunction Motions: Orexo sought to bar FDA approval of Actavis’s ANDA.
- Claim Construction: Court adopted constructions favoring Orexo's interpretation of formulations and ratios.
- Discovery and Expert Reports: Extensive disclosures about formulation ingredients and patent validity.
- Summary Judgment: Pending at last update, focusing on validity and infringement questions.
- Trial Date: Not set; case likely to proceed to a Markman hearing and trial based on infringement and validity issues.
Infringement and Validity Challenges
- Actavis argued that the patent claims are obvious in light of prior art references, including earlier formulations and patent disclosures.
- Orexo counters that the claimed ratios and controlled-release features involve unconventional choices and are non-obvious.
- Validity debates hinge on whether skilled persons would have combined prior art references to arrive at the claimed formulations.
Key Legal Issues
- Patent Validity: Obviousness challenges from Actavis.
- Infringement: Whether Actavis’s products infringe the asserted claims under the court’s construction.
- Patent Term & Patent Term Extension (PTE): Whether the patent’s life and term adjustments influence market strategies.
- FDA Orange Book Listing: The patent is listed with the FDA, which impacts generic approval under Paragraph IV litigation.
Market Impact
- The case's resolution influences the entry of generic buprenorphine/naloxone formulations.
- Likelihood of settlement or patent settlement agreements suspected, given the pattern of similar cases.
- Patent litigation delays generic competition, affecting drug pricing and availability.
Strategic Implications
- Orexo’s patent builds a barrier against generics for formulations with specific ratios and controlled-release mechanisms.
- Actavis’s potential challenges could reduce patent strength, leading to market entry.
- Patent validity and infringement rulings will shape licensing, settlement, or further litigations.
Key Takeaways
- The case addresses formulation-specific patent rights for buprenorphine/naloxone.
- Validity disputes focus on obviousness, common in generic patent litigations.
- Court’s claims construction will influence infringement outcomes.
- The dispute affects market dynamics for a crucial addiction treatment.
- Pending decisions may lead to settlement, invalidity rulings, or a trial.
FAQs
1. What are the main points of contention in this case?
Validity of Orexo’s '514 patent and whether Actavis’s products infringe its claims.
2. How does the patent protect Orexo’s formulation?
By covering specific ratios and controlled-release properties that are alleged to be inventive.
3. What are the implications if the patent is invalidated?
Generic versions could enter the market earlier, reducing prices and increasing access.
4. When is a resolution likely?
Pending dispositive motions and trial scheduling typically determine timeline; patent validity rulings precede infringement decisions.
5. How does this case compare to similar drug patent litigations?
It follows standard Hatch-Waxman litigation patterns focusing on formulation patents and obviousness defenses.
Sources
[1] U.S. Patent No. 8,603,514, issued December 3, 2013.
[2] Federal Court Docket: Orexo AB v. Actavis Elizabeth LLC, 1:16-cv-01138.
